Thyrocare Technologies Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Thyrocare Technologies Ltd filed with BSE on 14 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Thyrocare reported consolidated revenue of Rs 224 crore for Q4 FY26, up 20% year-on-year, with full-year consolidated revenue at Rs 829 crore, up 21%. EBITDA margin for the quarter was 34% and profit after tax grew 128% year-on-year to Rs 48.7 crore. Management discussed expansion into genomics and allergy testing, growth in franchisee and partnership channels, and a final dividend of Rs 7 per equity share.
Numbers mentioned
Consolidated revenue: INR224 crores (Q4 FY26)
p. 8
“On a consolidated basis, revenue stood at INR224 crores, reflecting a healthy 20% year-on-year growth.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Stand-alone revenue: INR210 crores (Q4 FY26)
p. 8
“Starting with revenue, our stand-alone revenue came in at INR210 crores, which is up 21% year-on-year, driven by strong growth across franchisee and partnership business.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Gross margin: 74.7% (Q4 FY26)
p. 8
“Our consolidated gross margin has improved to 74.7%, an increase of over 113 basis points year-on-year.”
Vikram Gupta, page 8 of the filed PDF · View the filing
EBITDA margin: 34% (Q4 FY26)
p. 8
“Our EBITDA margin for the quarter was 34%, with EBITDA growing 31% year-on-year, supported by strong revenue growth and improved gross margins.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Profit after tax: INR48.7 crores (Q4 FY26)
p. 8
“Profit after tax stood at INR48.7 crores with a PAT margin of 21.7%.”
Vikram Gupta, page 8 of the filed PDF · View the filing
PAT growth: 128% year-on-year (Q4 FY26)
p. 8
“This represents a 128% year-on-year growth.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Full-year stand-alone revenue: INR774 crores (FY26)
p. 8
“For FY '26, stand-alone revenue reached INR774 crores while consolidated revenue stood at INR829 crores, reflecting a strong 21% year-on-year growth.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Pathology revenue growth: 22% (FY26)
p. 8
“Pathology revenue grew by 22% in FY '26, while radiology revenue saw a decline of 6% during the year.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Full-year EBITDA: INR262 crores (FY26)
p. 8
“On profitability, in absolute terms, EBITDA for the year stood at INR262 crores and profit after tax was INR163 crores, reflecting strong growth of 38% and 81% year-on-year.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Earnings per share: INR2.99 (FY26)
p. 8
“Earnings per share adjusted for last year bonus issue came in at INR2.99, which is up by 64% from INR1.82 last year.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Net cash and investments: INR230 crores plus (As on 31 March 2026)
p. 8
“Our balance sheet remains strong with a net cash and investment of INR230 crores plus and zero debt as on 31 March, '26.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Cash from operating activities: INR213 crores (FY26)
p. 8
“On the cash flows, we generated INR213 crores from operating activities after tax during the year.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Final dividend: INR7 per equity share (FY26)
p. 8
“Board of Directors has recommended a final dividend of INR7 per equity share for the year ended March 31, 2026.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Tests processed: 210 million (FY26)
p. 4
“As a result, we processed 210 million tests in FY '26, which grew by 23% year-on-year.”
Rahul Guha, page 4 of the filed PDF · View the filing
Patients served: 19.2 million (FY26)
p. 4
“We serve 19.2 million patients in FY '26, which increased by 15% year-on-year.”
Rahul Guha, page 4 of the filed PDF · View the filing
Franchisee count: 10,800 active franchisees (Q4 FY26)
p. 5
“our franchisee base has reached its highest ever level of 10,800 active franchisees in Q4 FY '26”
Rajdeep Panwar, page 5 of the filed PDF · View the filing
Franchisee business growth: 21% year-on-year (Q4 FY26)
p. 5
“In FY '26, franchisee business delivered 18% Y-o-Y growth and in Q4 FY '26, 21% Y-o-Y growth.”
Rajdeep Panwar, page 5 of the filed PDF · View the filing
Partnership business growth: 23% (Q4 FY26)
p. 5
“In FY '26, partnership business grew at 32% year-on-year. And in Q4 FY '26, the growth was 23%.”
Rajdeep Panwar, page 5 of the filed PDF · View the filing
Jaanch growth: 66% (Q4 FY26)
p. 4
“the highlight was Jaanch, which grew at 66% this quarter year-on-year, showing the move towards more specialized disease-specific testing even in the annual health checkup space.”
Rahul Guha, page 4 of the filed PDF · View the filing
Complaints per million tests: 3.06 (Q4 FY26)
p. 4
“complaints reducing to 3.06 per million tests, thus sustaining a Six Sigma level of performance”
Rahul Guha, page 4 of the filed PDF · View the filing
Average turnaround time: 3.43 hours (Q4 FY26)
p. 4
“we delivered an average turnaround time of 3.43 hours from sample receipt, supported by our laboratory operations and a strong well-integrated logistics backbone.”
Rahul Guha, page 4 of the filed PDF · View the filing
Samples processed: 80.3 lakh samples (Q4 FY26)
p. 13
“We processed 80.3 lakh samples in Q4 of FY'26.”
Rahul Guha, page 13 of the filed PDF · View the filing
Tanzania revenue growth: 75% (FY26)
p. 8
“On the international front, our Tanzania operations, though small in base but has also grown by 75% for us year-on-year.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Insurance segment growth: 45% (FY26)
p. 19
“year-on-year, we've grown at almost 45%, right, in the insurance space.”
Rahul Guha, page 19 of the filed PDF · View the filing
Aarogyam mix and growth: 33% of overall mix, 19-20% growth (FY26)
p. 17
“Aarogyam will be about 33% of our overall mix and year-on-year growth it would have grown at about 19%, 20%.”
Rahul Guha, page 17 of the filed PDF · View the filing
Capex payout: INR20 crores (FY26)
p. 15
“that INR20 crores is the capex payout number, which you are looking in the cash flow.”
Vikram Gupta, page 15 of the filed PDF · View the filing
Total capitalization: approximately INR35 crores (FY26)
p. 16
“So, total capitalization of approximately INR35 crores across new labs, new capacity, etcetera, what we have done in -- which includes genomics.”
Vikram Gupta, page 16 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Gross margin — 73% to 74%
stated conditionally by Rahul Guha
p. 11
“So, I think you can expect the steady-state margins for the business to be around 73% to 74%, barring any abnormal price hike in reagents that may come out as a consequence of the war or the supply chain side.”
Rahul Guha, page 11 of the filed PDF · View the filing
Test volume growth — mid- to high teens · FY27
stated as an aspiration by Rahul Guha
p. 12
“I would say a mid- to high teens is a good growth expectation for next year, of which I expect volume growth to be the maximum driver, right?”
Rahul Guha, page 12 of the filed PDF · View the filing
Revenue mix from volume vs price — 75% from volume, 25% from mix · FY27
stated firmly by Rahul Guha
p. 12
“I would say almost 75% of the revenue will come from volume and maybe about 25% from mix. We have no intention at this point in time to increase prices.”
Rahul Guha, page 12 of the filed PDF · View the filing
Franchisee additions — 500 per quarter
stated firmly by Rahul Guha
p. 14
“But I expect about 500 per quarter is -- because we have resourced that way, right?”
Rahul Guha, page 14 of the filed PDF · View the filing
Specialty mix of business — 15% to 20% · 3 years
stated as an aspiration by Rahul Guha
p. 16
“See, our competitors specialty mix is roughly about 15% to 20%. I anticipate in 3 years reaching that level within Thyrocare as well.”
Rahul Guha, page 16 of the filed PDF · View the filing
EBITDA margin — around 34% · FY27
stated firmly by Rahul Guha
p. 19
“I expect that to be stable into the next year. As I mentioned, any further operating leverage that we get, we will continue to invest in growth.”
Rahul Guha, page 19 of the filed PDF · View the filing
Tax rate — 28% to 29%
stated firmly by Vikram Gupta
p. 18
“That is because of the deferred tax timing difference. And going forward, we expect our tax rate of 28% to 29%.”
Vikram Gupta, page 18 of the filed PDF · View the filing
Maintenance capex — roughly INR40 crores
stated firmly by Rahul Guha
p. 16
“Maintenance capex is roughly about INR40 crores with new expansion and all of that. We expect the capex to be in that range.”
Rahul Guha, page 16 of the filed PDF · View the filing
Specialty capex — INR5 crores to INR8 crores
stated firmly by Rahul Guha
p. 13
“See, the capex investments would not be much. They would be in the tune of about INR5 crores to INR8 crores, right?”
Rahul Guha, page 13 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said margins should stabilize around 73-74% due to vendor negotiations and volume-driven discounts, and clarified Tanzania has not yet broken even.
Answered by Rahul Guha
Asked by Raman KV: What is driving the gross margin expansion and is it the new normal, and has Tanzania breakeven contributed?
p. 12
“Yes. See, we still haven't broken even in Tanzania, right? So, I would say we've been in Tanzania now about 18 months odd and we still haven't broken even.”
Rahul Guha, page 12 of the filed PDF · View the filing
Management declined to give details, saying the strategy will become clear in a couple of quarters as they are consumers of allied diagnostic tests and plan to launch their own brand.
Answered by Rahul Guha
Asked by Yash Doshi: What is the new allied consumables/diagnostics business mentioned in the press release?
p. 13
“I would like to keep it internal to the company for the next 1 or 2 quarters because we are just working on the overall launch plan.”
Rahul Guha, page 13 of the filed PDF · View the filing
Management said franchisee additions run at about 500 per quarter (roughly 1,500 for three active quarters, up from earlier 1,200 guidance) and expects average revenue per franchisee to increase rather than franchisee count.
Answered by Rahul Guha
Asked by Chintan Sheth: How does vials per franchisee move as test menu expands, and is 500 franchisee additions per quarter a change from prior guidance?
p. 15
“So against 1,200, I think we are now comfortably achieving 1,500. So, that's what we are doing.”
Rahul Guha, page 15 of the filed PDF · View the filing
Management explained that growth is driven by franchise addition rather than capex, and total capitalization for FY26 was around Rs 35 crore including genomics investments.
Answered by Rahul Guha
Asked by Surya Patra: What is the capex plan for FY27 given genomics and specialty investments?
p. 16
“So from that point of view, our growth driver is not lab count and capex. Our growth driver is actually franchise addition and that is very asset-light, as you know, because we don't have any company-owned stores.”
Rahul Guha, page 16 of the filed PDF · View the filing
Management guided specialty mix to reach 15-20%, in line with competitors, within three years.
Answered by Rahul Guha
Asked by Surya Patra: What test mix share can specialty/genomics reach in 3 years?
p. 16
“See, our competitors specialty mix is roughly about 15% to 20%. I anticipate in 3 years reaching that level within Thyrocare as well.”
Rahul Guha, page 16 of the filed PDF · View the filing
Management said there has been no availability disruption since supply routes via Europe, but vendors have requested price increases due to the dollar.
Answered by Rahul Guha
Asked by Bino Pathiparampil: Is the Middle East situation affecting reagent availability or pricing?
p. 18
“Of course, with the dollar being where it is, right, many of our vendors has come back requesting for price increases.”
Rahul Guha, page 18 of the filed PDF · View the filing
Management said the lower tax rate this year was due to deferred tax timing differences and expects tax rate of 28-29% going forward.
Answered by Vikram Gupta
Asked by Yash Doshi: What will the tax rate be going forward given the deferred tax benefit this year?
p. 18
“Yes. That is because of the deferred tax timing difference. And going forward, we expect our tax rate of 28% to 29%.”
Vikram Gupta, page 18 of the filed PDF · View the filing
Management estimated the overall pathology market at Rs 50,000-60,000 crore, with specialty at 15-20% of that, implying a Rs 7,000-10,000 crore opportunity.
Answered by Rahul Guha
Asked by Ibrahim: What is the market opportunity for specialty testing and allied services in the next 2-3 years?
p. 19
“See, specialty testing, overall pathology market is estimated to be between INR50,000 crores and INR60,000 crores. And of that, roughly 15% to 20% is estimated to be the specialty space.”
Rahul Guha, page 19 of the filed PDF · View the filing
Management said the insurance segment grew about 45% year-on-year despite being nascent, but declined to give a specific segment-level guidance for next year.
Answered by Rahul Guha
Asked by Shubham Harne: How has the insurance business performed and what are growth expectations for next year?
p. 19
“I don't comment on individual segments. As I said, I have given an overall revenue guidance.”
Rahul Guha, page 19 of the filed PDF · View the filing
Management said it does not expect margin upside from specialty in FY27 given its nascent stage, and expects overall EBITDA margin to remain stable near 34%.
Answered by Rahul Guha
Asked by Yash Doshi: Will EBITDA margins expand due to the specialty segment going forward?
p. 19
“So, I don't expect -- and I will not build any major upside from the EBITDA margin side on the specialty sales in FY27.”
Rahul Guha, page 19 of the filed PDF · View the filing
Risks flagged
Potential reagent price increases due to currency and geopolitical supply chain pressures
p. 18
“But should the situation continue, I think, definitely, raw material prices will increase and then we will have to evaluate how we pass it on.”
Rahul Guha, page 18 of the filed PDF · View the filing
One-off decline in partnership segment growth due to normalized insurance pricing and lower camp activity versus prior year's Maha Kumbh boost
p. 6
“This dip is primarily because last year, we had a one-off boost in our partnership business, primarily due to an aggressive push on camps, especially during the Maha Kumbh period and the initial investment to build traction in the insurance segment as well.”
Rajdeep Panwar, page 6 of the filed PDF · View the filing
Radiology business growth impacted temporarily by strategic consolidation of centers
p. 8
“In radiology, as covered in earlier calls also, we undertook some strategic consolidation of centers during the year. While this has temporary impact on the growth, the overall financial performance has improved with a stronger bottom line.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Tanzania operations have not yet reached breakeven
p. 12
“So, I would say we've been in Tanzania now about 18 months odd and we still haven't broken even.”
Rahul Guha, page 12 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.